Advantages of sensor‐augmented insulin pump therapy for pregnant women with type 1 diabetes mellitus
Abstract Aims/Introduction To evaluate the efficacy of sensor‐augmented pump (SAP) for improving obstetric and neonatal outcomes among pregnant women with type 1 diabetes mellitus by comparing it with continuous subcutaneous insulin infusion plus self‐monitoring of blood glucose (continuous subcutan...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.14075 |
| _version_ | 1797447634512773120 |
|---|---|
| author | Hitomi Imafuku Kenji Tanimura Naohisa Masuko Masako Tomimoto Yutoku Shi Akiko Uchida Masashi Deguchi Kazumichi Fujioka Akane Yamamoto Kei Yoshino Yushi Hirota Wataru Ogawa Yoshito Terai |
| author_facet | Hitomi Imafuku Kenji Tanimura Naohisa Masuko Masako Tomimoto Yutoku Shi Akiko Uchida Masashi Deguchi Kazumichi Fujioka Akane Yamamoto Kei Yoshino Yushi Hirota Wataru Ogawa Yoshito Terai |
| author_sort | Hitomi Imafuku |
| collection | DOAJ |
| description | Abstract Aims/Introduction To evaluate the efficacy of sensor‐augmented pump (SAP) for improving obstetric and neonatal outcomes among pregnant women with type 1 diabetes mellitus by comparing it with continuous subcutaneous insulin infusion plus self‐monitoring of blood glucose (continuous subcutaneous insulin infusion [CSII]/SMBG). Materials and Methods This retrospective cohort study included 40 cases of pregnancy complicated by type 1 diabetes mellitus treated with SAP (SAP group), and 29 cases of pregnancy complicated by type 1 diabetes mellitus treated with CSII/SMBG (CSII/SMBG group). The obstetric and neonatal outcomes were compared between the two groups. Results The median of the glycoalbumin levels in the first (18.8% vs 20.9%; P < 0.05) and second (15.4% vs 18.0%; P < 0.05) trimesters, the hemoglobin A1c levels in the peripartum period (6.1% vs 6.5%; P < 0.05) and the standard deviation score of birthweights (0.36 vs 1.52; P < 0.05) were significantly lower in the SAP group than in the CSII/SMBG group. The incidence rate of large for gestational age newborns was significantly lower in the SAP group than in the CSII/SMBG group (27.5% vs 65.5%; P < 0.05). No significant differences in the incidence rates of hypertensive disorders of pregnancy, small for gestational age, respiratory distress syndrome, neonatal hypoglycemia, hypervolemia and hyperbilirubinemia were observed between the groups. Conclusion The present study showed that SAP therapy is more effective in preventing large for gestational age newborns in pregnant women with type 1 diabetes mellitus than CSII/SMBG. |
| first_indexed | 2024-03-09T13:58:45Z |
| format | Article |
| id | doaj.art-26ecd19cdcfb428bb893155b2baff059 |
| institution | Directory Open Access Journal |
| issn | 2040-1116 2040-1124 |
| language | English |
| last_indexed | 2024-03-09T13:58:45Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj.art-26ecd19cdcfb428bb893155b2baff0592023-11-30T11:41:37ZengWileyJournal of Diabetes Investigation2040-11162040-11242023-12-0114121383139010.1111/jdi.14075Advantages of sensor‐augmented insulin pump therapy for pregnant women with type 1 diabetes mellitusHitomi Imafuku0Kenji Tanimura1Naohisa Masuko2Masako Tomimoto3Yutoku Shi4Akiko Uchida5Masashi Deguchi6Kazumichi Fujioka7Akane Yamamoto8Kei Yoshino9Yushi Hirota10Wataru Ogawa11Yoshito Terai12Department of Obstetrics and Gynecology Kobe University Graduate School of Medicine Kobe JapanDepartment of Obstetrics and Gynecology Kobe University Graduate School of Medicine Kobe JapanDepartment of Obstetrics and Gynecology Kobe University Graduate School of Medicine Kobe JapanDepartment of Obstetrics and Gynecology Kobe University Graduate School of Medicine Kobe JapanDepartment of Obstetrics and Gynecology Kobe University Graduate School of Medicine Kobe JapanDepartment of Obstetrics and Gynecology Kobe University Graduate School of Medicine Kobe JapanDepartment of Obstetrics and Gynecology Kobe University Graduate School of Medicine Kobe JapanDepartment of Pediatrics Kobe University Graduate School of Medicine Kobe JapanDivision of Diabetes and Endocrinology, Department of the Internal Medicine Kobe University Graduate School of Medicine Kobe JapanDivision of Diabetes and Endocrinology, Department of the Internal Medicine Kobe University Graduate School of Medicine Kobe JapanDivision of Diabetes and Endocrinology, Department of the Internal Medicine Kobe University Graduate School of Medicine Kobe JapanDivision of Diabetes and Endocrinology, Department of the Internal Medicine Kobe University Graduate School of Medicine Kobe JapanDepartment of Obstetrics and Gynecology Kobe University Graduate School of Medicine Kobe JapanAbstract Aims/Introduction To evaluate the efficacy of sensor‐augmented pump (SAP) for improving obstetric and neonatal outcomes among pregnant women with type 1 diabetes mellitus by comparing it with continuous subcutaneous insulin infusion plus self‐monitoring of blood glucose (continuous subcutaneous insulin infusion [CSII]/SMBG). Materials and Methods This retrospective cohort study included 40 cases of pregnancy complicated by type 1 diabetes mellitus treated with SAP (SAP group), and 29 cases of pregnancy complicated by type 1 diabetes mellitus treated with CSII/SMBG (CSII/SMBG group). The obstetric and neonatal outcomes were compared between the two groups. Results The median of the glycoalbumin levels in the first (18.8% vs 20.9%; P < 0.05) and second (15.4% vs 18.0%; P < 0.05) trimesters, the hemoglobin A1c levels in the peripartum period (6.1% vs 6.5%; P < 0.05) and the standard deviation score of birthweights (0.36 vs 1.52; P < 0.05) were significantly lower in the SAP group than in the CSII/SMBG group. The incidence rate of large for gestational age newborns was significantly lower in the SAP group than in the CSII/SMBG group (27.5% vs 65.5%; P < 0.05). No significant differences in the incidence rates of hypertensive disorders of pregnancy, small for gestational age, respiratory distress syndrome, neonatal hypoglycemia, hypervolemia and hyperbilirubinemia were observed between the groups. Conclusion The present study showed that SAP therapy is more effective in preventing large for gestational age newborns in pregnant women with type 1 diabetes mellitus than CSII/SMBG.https://doi.org/10.1111/jdi.14075Pregnant womenSensor‐augmented pumpType 1 diabetes mellitus |
| spellingShingle | Hitomi Imafuku Kenji Tanimura Naohisa Masuko Masako Tomimoto Yutoku Shi Akiko Uchida Masashi Deguchi Kazumichi Fujioka Akane Yamamoto Kei Yoshino Yushi Hirota Wataru Ogawa Yoshito Terai Advantages of sensor‐augmented insulin pump therapy for pregnant women with type 1 diabetes mellitus Journal of Diabetes Investigation Pregnant women Sensor‐augmented pump Type 1 diabetes mellitus |
| title | Advantages of sensor‐augmented insulin pump therapy for pregnant women with type 1 diabetes mellitus |
| title_full | Advantages of sensor‐augmented insulin pump therapy for pregnant women with type 1 diabetes mellitus |
| title_fullStr | Advantages of sensor‐augmented insulin pump therapy for pregnant women with type 1 diabetes mellitus |
| title_full_unstemmed | Advantages of sensor‐augmented insulin pump therapy for pregnant women with type 1 diabetes mellitus |
| title_short | Advantages of sensor‐augmented insulin pump therapy for pregnant women with type 1 diabetes mellitus |
| title_sort | advantages of sensor augmented insulin pump therapy for pregnant women with type 1 diabetes mellitus |
| topic | Pregnant women Sensor‐augmented pump Type 1 diabetes mellitus |
| url | https://doi.org/10.1111/jdi.14075 |
| work_keys_str_mv | AT hitomiimafuku advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT kenjitanimura advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT naohisamasuko advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT masakotomimoto advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT yutokushi advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT akikouchida advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT masashideguchi advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT kazumichifujioka advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT akaneyamamoto advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT keiyoshino advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT yushihirota advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT wataruogawa advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus AT yoshitoterai advantagesofsensoraugmentedinsulinpumptherapyforpregnantwomenwithtype1diabetesmellitus |